<Blinded Review: TIME_ANON_0445>
**Composite Score:** 7.6 / 10.0 (Rigor: 2.6/3.5 | Claims: 2.0/2.5 | Biology: 1.6/2.0 | Reproducibility: 1.4/2.0)
**Bias Category:** None (Methodologically Sound)
**Verdict:** Minor Revision
**Study Modality:** Wet-Lab Primary Experimental
**Technology Maturity:** Mature/Classical
**Epistemic Stage:** Basic/Mechanistic Discovery

OVERALL_SCORE: 7.6/10
VERDICT: PASS
ESTIMATED_DECADE: 2000s

---

### 1. Executive Summary (SUMMARY)
This study identifies and characterizes an evolutionarily conserved alternative promoter located within the 3' half of the first intron of the proto-oncogene *c-fos* (+619 to +849 relative to the canonical mouse TSS). Using comparative genomics across seven vertebrates, EMSA supershift/competition assays, transient luciferase reporter assays (`fiL`) in NIH3T3 fibroblasts, pronuclear-injected NLS-LacZ transgenic mouse lines (`fiZ`, 7 founders, 5 expressing lines), and primer-walking RT-qPCR on embryonic and adult tissues, the authors show that the intronic region contains functional TRE, CRE, and TATA motifs, responds to $\text{Ca}^{2+}$/cAMP signaling and CREB or c-Fos/c-Jun co-expression, drives spatially restricted reporter expression in E12.5–E13.5 mammary bud mesenchyme and developing/adult CNS, and initiates an endogenous nested transcript between $+740$ and $+819$. The multi-modal progression from sequence conservation to *in vivo* transgenic and endogenous transcript validation is thorough, though weakened by the inability to detect the predicted N-terminally truncated protein ($\text{c-Fos}\Delta\text{N}$) *in vivo* and the absence of $5'\text{-RACE}$ to map the exact nucleotide start site.

### 2. Methodological & Statistical Audit (STRENGTHS & WEAKNESSES & METHODOLOGICAL AUDIT)
#### Strengths
* **Multi-Line Transgenic Validation with Nuclear Localization Control:** Rather than relying on a single founder, the authors generated 7 transgenic founder lines (5 expressing) with an SV40 NLS fused to *lacZ*, enabling unambiguous histological distinction on cryosections between transgene-driven nuclear $\beta$-galactosidase in mammary bud mesenchyme/ventral spinal cord (4/5 and 3/5 lines, Table 1) and endogenous cytoplasmic $\beta$-galactosidase in nasal pits, stomach, and kidney.
* **Rigorous Pre-mRNA Controls in Endogenous RT-qPCR Mapping:** Because an intronic amplicon could easily detect unspliced canonical *c-fos* pre-mRNA or genomic DNA contamination, the authors included $-\text{RT}$ controls and designed three upstream intronic primers (`0.8`, `0.9`, and `1`) paired with the same exon 2 reverse primer (`RT1`), calibrating each primer pair against standard dilution curves of a cloned *c-fos* plasmid (Figure 6A–C). The sharp jump in transcript abundance between primer `1` ($+740$) and primer `2` ($+819$) rules out canonical pre-mRNA readthrough.
* **Complete EMSA Specificity Controls:** Figure 2 combines cold wild-type, single-site mutant (`mTRECRE`, `TREmCRE`), and double-mutant (`mTREmCRE`) competition with seven specific antibodies to dissect AP-1 and CREB/ATF-1 binding to the adjacent intronic TRE and CRE motifs.

#### Weaknesses & Methodological Audit
* **Absence of $5'\text{-RACE}$ / CAGE and Unverified Protein Translation:** While primer walking narrows the intronic initiation window to $+740\text{--}+819$, $5'\text{-RACE}$ or RNase protection was not performed to define the exact $5'$ cap site. More importantly, as the authors acknowledge in the Discussion, Western blotting with N- and C-terminal c-Fos antibodies failed to detect the predicted Met-111 truncated isoform ($\text{c-Fos}\Delta\text{N}$) in adult tissue extracts, leaving open whether the intronic transcript is translated *in vivo* or acts as a non-coding/regulatory RNA.
* **Site-Directed Mutagenesis Not Tested in the Functional Luciferase Assay:** Although mutated TRE and CRE oligonucleotides (`mTRECRE`, `TREmCRE`, `mTREmCRE`) were used for EMSA competition (Figure 2A), those mutations were not introduced into the `fiL` luciferase reporter to prove that the forskolin, A23187, CREB, and c-Fos/c-Jun inductions in Figure 3C–D depend directly on the intronic CRE and TRE sites.
* **Unspecified Post-Hoc Multiple Comparison Procedure in ANOVA:** Figures 3 and 6 state that "Statistical analysis of variance (ANOVA) was performed ($*: p<0.05; **: p<0.01$ relative to control)" for $n=4$ to $7$ replicates, but do not specify which post-hoc test (e.g., Dunnett's or Tukey's) was used to control family-wise error across multiple treatments/tissues.

### 3. Biological / Experimental Grounding & Claim Proportionality
* **Claim 1: The 3' region of *c-fos* intron 1 is highly conserved across vertebrates and contains functional TRE and CRE sites that drive $\text{Ca}^{2+}$/cAMP-inducible promoter activity `[Well Supported]`.** Cross-species alignment, EMSA competition/supershifts, and Renilla-normalized dual-luciferase assays in NIH3T3 cells ($n=5\text{--}7$) provide converging support.
* **Claim 2: The intronic promoter drives developmentally restricted expression in embryonic mammary bud mesenchyme and CNS and produces an endogenous nested mRNA `[Well Supported]`.** Reproducible expression across 4/5 independent transgenic lines in E12.5 mammary mesenchyme and 3/5 in spinal cord/adult brain, corroborated by plasmid-calibrated RT-qPCR showing a step-change between $+740$ and $+819$ in E12.5 mammary buds and adult cortex, firmly establishes *in vivo* transcription.
* **Claim 3: The intronic transcript encodes a functional N-terminally truncated $\text{c-Fos}\Delta\text{N}$ protein insensitive to glucocorticoid receptor trans-repression `[Fragile]`.** Presented appropriately as a hypothesis in the Discussion, this claim currently rests on unpublished transient transactivation data and sequence deduction without *in vivo* protein detection.

### 4. Reproducibility & Data Completeness
* **Accession Numbers and Oligonucleotides:** All seven species accession numbers (`V01512`, `AJ132510`, `V00727`, `M18043`, `NC_007131`, `ENSTRUG00000010579`) and all cloning, EMSA (wild-type and mutant), genotyping, and RT-qPCR primer sequences (`RT1`, primers `0.8`, `0.9`, `1`, `2`, `3`) are fully documented in the Materials and Methods.
* **Reagent and Protocol Detail:** Drug concentrations, plasmid amounts, transgenic staining buffers, and LightCycler 480 thermal cycling parameters are specified with sufficient detail for independent replication.
</Blinded Review: TIME_ANON_0445>
